[Ip-health] Supreme Court dismisses Novartis AG plea for patent of cancer drug Glivec

Gopa Kumar kumargopakm at gmail.com
Sun Mar 31 23:17:25 PDT 2013


Supreme Court dismisses Novartis AG plea for patent of cancer drug Glivec
*Reuters* Posted online: Mon Apr 01 2013, 11:03 hrs
*New Delhi : *Supreme Court dismissed Swiss drugmaker Novartis AG's attempt
to win patent protection for its cancer drug Glivec, a serious blow to
Western pharmaceutical firms who are increasingly focusing on India to
drive sales.

The decision also sets a benchmark for several intellectual property
disputes in India, where many patented drugs are unaffordable for most of
its 1.2 billion people, 40 percent of whom earn less than $1.25 a day.

India's domestic drugs market is the 14th largest globally, but with annual
growth of 13-14 percent and the world's second biggest population, it has
massive potential at a time when traditional developed markets have slowed
down.

The Supreme Court's landmark ruling is likely to affect several other
companies and their branded medicines.

Pfizer Inc's cancer drug Sutent and Roche Holding AG's hepatitis C
treatment Pegasys lost their patented status in India last year, and
Monday's ruling will make it tougher for them to win back patent protection.

"Henceforth, multinational pharma companies are likely to want that their
patents are first recognised in India before launch of a patented product,"
said Ameet Hariani, managing partner at Mumbai-based law firm Hariani & Co.

Novartis has previously that said it needs legal certainty if it is to plan
further investment in drug research in India.

The ruling is a boost for healthcare activists who want the government to
make medicines cheaper in a country where patented drugs constitute under
10 percent of total drug sales.

Novartis has been fighting since 2006 to win a patent for an amended form
of Glivec. In 2009 it took its challenge against a law that bans patents on
newer but not radically different forms of known drugs to the Supreme Court.

India has refused protection for Glivec on the grounds that it is not a new
medicine but an amended version of a known compound. By contrast, the newer
form of Glivec has been patented in nearly 40 countries including the
United States, Russia and China.

The Supreme Court decided that Glivec does not satisfy the "novelty"
aspect, Pravin Anand, lawyer for Novartis, told reporters.

Shares in Novartis India Ltd, the Indian unit of the drugmaker, fell over 5
percent after the verdict.



More information about the Ip-health mailing list